A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...

In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...

Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32-million ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...

Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

In Canada, 1 in 12 people live with a rare disease, and for most people suffering from these diseases, the cost of treatment is unaffordable ...

Wealth Advisors LLC raised its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 3.9% during the 4th quarter, ...

Claro Advisors LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & ...